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Pertussis  is a serious  infectious  disease  of  the respiratory  tract  caused  by  the  gram-negative  bacteria  Bor-
detella  pertussis.  There  has  been  a reemergence  of  this  disease  within  the  population  of several  countries
that  have  well  established  vaccination  programs.  Analyzes  of  clinical  isolates  suggest  an  antigenic  diver-
gence  between  the  vaccine-based  strains  to the circulating  strains.  Although  antibodies  against  P.69
are  involved  in the  observed  protective  immunity,  the sequences  recognized  as  antigenic  determinants
in  P.133,  the  precursor  for P.69,  P.3.4  and  P.30,  have  not  be  determined.  Here, the  precise  mapping  of
linear  B-cell  epitopes  within  the  predicted  P.133  pertactin  sequences  was  accomplished  using  the  SPOT-
synthesis  of  peptide  arrays  onto  cellulose  membranes  and  screening  with  murine  sera generated  by
vaccination  with  either  the  Pertussis  cellular  (miPc)  or  Pertussis  acellular  (miPa)  vaccine.  A total  of  23
major  epitopes  were  identiﬁed  by sera  from  miPc  vaccinated  mice,  while  thirteen  were  identiﬁed  by
sera  from  miPa  vaccinated  mice.  Of these  epitopes,  12  epitopes  were  speciﬁcally  identiﬁed  by antibodies
produced  in  response  to  the  miPc  vaccine  and  two  were  speciﬁc  to the  miPa  vaccine.  These  epitopes
were  distributed  throughout  the  pertactin  sequence  but  a signiﬁcant  number  were  concentrated  to  the
P.30  Prn  segment.  An  analysis  of  the  epitope  correlation  homologies  indicated  that  the  variations  from
the  observed  mutations  in pertactin  would  not  constitute  a problem  using  these  vaccines.  In addition,
the  mapping  of epitopes  demonstrated  a  higher  number  of  linear  B-cell  epitopes  immunized  with  the Pc
vaccine  than  the Pa vaccine.. Introduction
Pertussis, or whooping cough, is an acute infectious disease of
he bacterium Bordetella pertussis that is especially dangerous in
oung children. There has been resurgence over the past 15 years
f infections in countries with a high compliance for vaccine admin-
stration [1]. Several explanations have been suggested for the
eemergence of B. pertussis including improvements in diagnosis,
 waning of immunity from vaccinations and an adaptation of the
Abbreviations: DTP, diphtheria–tetanus–pertussis vaccine; DTPa, diphtheria–
etanus–pertussis acellular vaccine; FHA, ﬁlamentous hemagglutinin; miPa, mice
mmunized with Pertussis acellular; miPc, mice immunized with Pertussis cellu-
ar; mAbs, monoclonal antibodies; Prn, pertactin Pertussis acellular; Pc, Pertussis
ellular; Pt, Pertussis toxin.
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undac¸ ão Oswaldo Cruz, IOC-FIOCRUZ, 21040900 Rio de Janeiro, RJ, Brazil.
el.: +55 21 38658183; fax: +55 21 38658240.
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ttp://dx.doi.org/10.1016/j.vaccine.2014.09.019
264-410X/© 2014 Elsevier Ltd. All rights reserved.©  2014  Elsevier  Ltd. All  rights  reserved.
circulating B. pertussis population to induced immunity [2]. Genetic
comparisons of clinical isolates to the strains used for vaccine pro-
duction revealed sequence divergence [3–15], which suggests that
pathogen adaptation and innate resistance are the most probable
causes for the increased occurrence of infection [5,16,17].
Of particular interest is the protein pertactin (P.69 Prn), which
is a key component of vaccines since antibody titers against
P.69 Prn correlate with protective immunity [18,19] and clinically
observed protection [20–22]. Multiple polymorphisms have been
described deﬁning 13 variants [2,23,24,19] with variations limited
to two regions comprised of the repeats of Gly-Gly-X-X-Pro or
Pro-Gln-Pro that are designated as the r1 (aa 276–280) and r2 (aa
575–590/594–598) repeat, respectively. Greater variation has been
observed within r1, which is located proximal to the N-terminus
and ﬂanks an Arg-Gly-Asp (RGD) motif implicated in the ligand-
receptor interactions in eukaryotes [25,26].
Despite a number of studies in both animals and humans
demonstrating that P.69 Prn can elicit protective antibodies
[19,27,28], information about the sequences and locations of the
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-linear epitopes involved is limited to a few segments [29]. Most of
he continuous and discontinuous epitopes identiﬁed to date were
btained using various methodologies and sera from different hosts
30]. While these studies addressed the involvement of important
egments or domain in the toxins, to our knowledge the studies
id not compare the immune response elicited by the two types of
accines at the epitope level.
The analysis of the immune response obtained from vaccination
ith the two forms of vaccines, Pertussis cellular (Pc) and Pertussis
cellular (Pa), indicate that a robust protection is induced indepen-
ent of the process of antigen preparation [31]. The Pc vaccine is
repared using heat-killed bacteria, a physical process that dena-
ures proteins and destroys most of the discontinuous epitopes. Pa
accines, on the other hand, are prepared containing proteins that
re puriﬁed and ﬁxed with formaldehyde, which preserves most
pitopes [32]. However, the commonality between the two vac-
ines is linear B-cell epitopes, which suggests that their presence
s key to understanding the mechanisms of protection induced by
accination and its loss over time.
Our results conﬁrm and reﬁne those from previous studies by
dentifying the linear B-cell epitopes recognized in P.133 Prn (the
.69 Prn precursor) by antibodies generated through immunization
ith the two types of available vaccines. The identity of the epitopes
llowed an extensive comparison between the immunological
esponse against the cellular and acellular generated vaccines to
ddress the hypothesis that genetic drift was contributing to the
esurgence of pertussis in the world’s population.
. Material and methods
.1. Materials
Cellulose membranes were from Intavis Bioanalytical Instru-
ents (Germany). Sheep anti-mouse immunoglobulin was
btained from Promega Biosciences (CA, USA) and the SuperSignal
est Pico chemiluminescent substrate from Pierce (IL, USA). All
ther reagents and chemicals including amino acids were from
erck–Calbiochem (Darmstadt, Germany). The DTP vaccine con-
aining inactivated whole-cell bacterium of B. pertussis combined
ith formaldehyde inactivated diphtheria and tetanus toxoid
as obtained from Bio-Manguinhos (FIOCRUZ, RJ, Brazil). The
TPa vaccine (Prn, pertussis toxin, ﬁlamentous hemagglutinin
nd ﬁmbrial serotypes 2 & 3) was from GlaxoSmithKline. Both
he DTP and DTPa vaccine containe aluminum hydroxide as an
djuvant.
.2. Immunization of mice
NIH Swiss mice (12–16 g) were immunized with either DTP or
TPa vaccines reconstituted with saline and 2 IU (deﬁned by the
razilian National Immunization Program) administered in 0.5 ml
ith an interval of 21 days. For the DTPa vaccine, 2 IU contains
5 g PT, 25 g FHA and 8 g pertactin adsorbed to aluminum salts.
roups of 15 mice received injections from one of three different
ots of the DTP or one of three different lots of DTPa vaccine. Sera
as collected one week after the last inoculation, stored at −20 ◦C
nd pooled for each vaccine before use..3. Ethical aspects
All experiments involving animals were approved by ethi-
al committees and the approvals are acknowledged within the
anuscript.2 (2014) 6251–6258
2.4. Synthesis of the cellulose–membrane-bound peptide array
A peptide array was synthesized onto amino-PEG500-UC540 cel-
lulose membranes according to standard SPOT-synthesis protocols
[33] using an Auto-Spot Robot ASP222 (Intavis). The array was com-
prised of 179 peptides that covered the entire coding region of the
P.69 Prn precursor protein (Fig. 1). Each peptide was a 14-mer and
its sequence was offset from the previous by 5 amino acids. After
synthesis, membranes were either probed immediately or stored at
−20 ◦C until needed. The negative control was  an area without pep-
tide and the positive control was  the peptide IHLVNNESSEVIVHK
from Clostridium tetani precursor.
2.5. Measurement of spot signal intensities
Spot signal intensity was  measured as described previously [34].
Chemiluminescent signals were detected on a MF-ChemiBis 3.2
(DNR Bio-Imaging Systems, USA) at a resolution of 5 MP  and the
image analyzed with Total Lab Software (Nonlinear Dynamics, USA)
to quantify signal intensities and to deﬁne the empirical proba-
bility that the intensity from a spot was distinct from that of the
background signal using algorithms that compared the intensities
between background, spot area and negative controls.
2.6. Bioinformatics and in silicon analysis model
The complete sequence of B. pertussis pertactin (A4UTL5) was
used for epitope mapping and the other strains of B. pertussis
(Q03035, K4QEP0, K4TPW9, Q9L4E2, Q6U896, K4TCV0, Q9AIX8,
K0MTC8, J7RKB0, A4UTL5, F4LFL2, P14283) were retrieved from the
National Center for Biotechnology Information, USA (http://www.
ncbi.nlm.nih.gov). Multiple sequence alignments were performed
using the programs ClustalW (http://www.ebi.ac.uk/clustalw) and
BioEdit (http://www.mbio.ncsu.edu/BioEdit/bioedit. html).
The alignment of the P.69 Prn from the three major species, Bor-
detella spp. (B. pertussis (Tahoma I), Bordetella parapertussis (12822)
and Bordetella bronchiseptica (RB50), was performed using the
program Kodon (Applied Maths, Belgium). The predicted struc-
tural model of P.133 pertactin was  obtained by submission of the
sequence (A4UTL5) to the I-Tasser server [35,36].
3. Results
3.1. Epitope mapping
Epitopes in the pertactin precursor protein (900 aa) were iden-
tiﬁed based on recognition of peptides in a synthesized library by
murine antibodies immunized with a B. pertussis vaccine, either Pc
or Pa (see Materials and Methods). Fig. 1, Panels A and C present
the position of each peptide and the measured intensity from the
chemiluminescent detection of mouse IgG antibodies in sera pooled
from mice vaccinated with the Pc vaccine. The intensities were nor-
malized using 100% as deﬁned by the positive control (data not
shown). Panels B and D show the results from the reactivity of
IgG antibodies in pooled murine sera vaccinated with the Pa vac-
cine. A list of the peptides synthesized and their positions on the
membranes is presented in Panel E.
The pattern of reactivity for the antibodies generated in mice
immunized with the Pc vaccine demonstrated that a greater num-
ber of peptides were recognized than in mice immunized with the
Pa vaccine (Fig. 1A). An analysis of the sequences constituting the
peptides synthesized in reactive regions deﬁned 23 epitopes gener-
ated by the miPc vaccine while only 13 epitopes were created by the
miPa vaccine (Table 1). Twelve epitopes (Prn-1, Prn-2, Prn-3, Prn-4,
Prn-7, Prn-10, Prn-20, Prn-21, Prn-22, Prn-23, Prn-24, Prn-25) were
uniquely speciﬁed by the miPc vaccine and two  epitopes (Prn-14
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Fig. 1. Fine mapping of epitopes by sera from mice immunized with DTP ((A) and (C)) and DTPa ((B) and (D)) with the library (E) of the pertactin Bordetella pertussis protein
synthetic 15-mer peptides. Binding of antibody to individual peptides was detected by incubating the membrane with alkaline phosphatase goat anti-mouse immunoglobulin.
The  intensity of signal ((A) and (B)) was obtained by scanning of the membranes ((C) and (D)) probed with the antisera.
6254 F.R. da Silva et al. / Vaccine 3
Table 1
Epitopes of Bordetella pertussis P.133 Prn protein identiﬁed in this study by SPOT-
synthesis analysis.
Epitope Cellular vaccine Acellular vaccine Murine antibodies [39]
Prn-1 46–59 45–49
Prn-2 61–74 65–70
Prn-3 80–84 78–83
Prn-4 104–119 105–111
Prn-5 126–139 135–149 133–137
Prn-6 191–199 181–194 190–195
Prn-7 221–234 224–228
Prn-8 245–264 257–265 256–285
Prn-9 281–289 286–294 256–285
Prn-10 351–359 350–358/362–367
Prn-11 426–440 426–444 425–482
Prn-12 471–484 471–479 468–473
Prn-13 491–499 495–504
Prn-14 526–534 527–533
Prn-15 551–564
Prn-16 611–624 616–629 620–627
Prn-17 641–654 641–654 651–655
Prn-18 682–699 686–699 681–688
Prn-19 776–779 761–779
Prn-20 791–799
Prn-21 811–824
Prn-22 831–839
Prn-23 851–854
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Prn-25 876–889
nd Prn-15) by the sera of miPa vaccine (Table 1). The remaining
pitopes were common between the two vaccines (Table 1). Over-
ll, the epitopes were designated as Prn-1 to Prn-25 for this study.
.2. Localization of the B-epitopes within the P.133-Prn protein
The 25 linear B-epitopes identiﬁed by the SPOT-synthesis anal-
sis were distributed throughout the pertactin protein (Fig. 2). The
.133 pertactin protein gene contains three well deﬁned segments:
 signaling N-terminal extension (aa 1–34), P.69 Prn (aa 35–566)
nd the P.30 segment (aa 607–900) [19].
No reactivity was observed against the signal peptide in the ﬁrst
hirty-ﬁve amino acids by either vaccine. Thirteen epitopes were
dentiﬁed in the P.69 Prn segment by the miPc vaccine sera (Prn-1 to
rn-13) and 10 epitopes (Prn-5, Prn-6, Prn-8, Prn-9, Prn-11 to Prn-
5) by the miPa vaccine sera (Table 1). Neither the variable region
1 (aa 276–280) nor r2 (aa 575–590/594–598) displayed epitope.
The major response of the Pa vaccine was found within
equences between regions 1 and 2. Most of the identiﬁed epitopes
ere located in loop/coil structures, which were present on the
rotein surface and accessible to the solvent (Fig. 2).
The P.30 segment (aa 607–900) contained 10 epitopes (Prn-16 to
rn-25) recognized by miPc vaccine sera. Only four epitopes (Prn-
6 to Prn-19) were reactive to miPa vaccine sera (Table 1).
One sequence [300-GGXXP-304] is located directly after the
GD motif that could mediate interactions with epithelial cells [37].
hile the RGD motif (aa 260–272) from region 1 is part of an epi-
ope (Prn-8) recognized by sera of miPc (aa 245–265) and miPa
aa 257–265) vaccine sera, the adjacent sequence involved in the
pithelial adhesion is not present in this epitope (Table 1).
.3. Spatial location of the P.133 reactive epitopes
The tridimensional structure of mature P.69 pertactin has been
etermined to a resolution of 2.5 A˚ by X-ray diffraction, but no
tructure exists for the precursor, P.133 Prn. In our study, a pre-
icted structural model of the entire P.133 Prn was  obtained
Fig. 2) with a conﬁdence score equal to −2.16 and a TM-score of
.47 ± 0.15 (borderline quality) and displays the spatial localization2 (2014) 6251–6258
of the most reactive epitopes identiﬁed by the SPOT-synthesis array
experiments. Most of the linear epitopes were located in coil/loop
structures in the P.133 protein structure. The hydropathy plot of
the protein also suggested that all of the epitopes were present on
the surface of the proteins (data not shown).
3.4. Cross-immunity conferred by strains of B. pertussis
To investigate the cross-immunity conferred by the B. pertus-
sis pertactin protein, 12 sequences deposited in NCBI data bank
were aligned to compare the sequences of the epitopes. This anal-
ysis showed that, in totality, all of the epitopes identiﬁed by sera
from immunized mice were identical between the different strain
sequences (Fig. 3). The high conservation of the structure of the
epitopes suggests that a strong cross-immunity is induced by
immunization.
The epitopes identiﬁed in this work by the SPOT-synthesis
approach compared to those identiﬁed in the literature by other
methodologies and murine immune sera [37,38] or monoclonal
antibodies [37] were 100% correlative. Our epitope mapping
revealed nine (Prn-13, Prn-15, Prn-19 to Prn-25) new murine epi-
topes (Table 1).
3.5. Correlation of pertactin within Bordetella sp
As shown in Fig. 4, the pertactin proteins shares a high level of
structural similarity and therefore all of linear epitopes identiﬁed
with other Bordetella sp adhesins proteins.
4. Discussion
Studies in animals and humans have indicated that immu-
nity against pertussis was highly dependent on the inclusion of
pertactin in vaccines through correlations between anti-pertactin
antibodies and clinical protection. Pertactin belongs to a family of
secreted proteins, which is proteolytically processed at its N- and
C-termini to produce P.69 and P.30 located at the cell surface and in
the outer membrane, respectively [38]. A major difference between
the two available Pertussis vaccines is that P.69 pertactin is only
included in the Pa vaccine while both proteins segments are present
in the Pc vaccine.
In practice, vaccination with either vaccine is effective at elici-
ting a protective immune response. The mapping results show that
the immune response in mouse to each, while comparable, was
not identical (Fig. 1). Sera from mice immunized with the Pc vac-
cine recognized 23 epitopes and with the Pa vaccine, 11 epitopes
were identiﬁed (Fig. 1 and Table 1). With regards pertactin, the
most robust immune responses from the Pc vaccine were directed
against both the N-terminus (P.69 Prn) and C-terminus (P.30 Prn).
For the Pa vaccine, reactivity was  directed against the segment
spanning regions 1 and 2.
Immunizing mice with the Pc or Pa vaccine induced distinct and
speciﬁc antibodies that, along with the decreasing antigenicity of
P.69 Prn by the Pa vaccine, could be explained by the effects of
chemical treatments necessary for detoxiﬁcation of preparations.
Although the modiﬁcations from formaldehyde treatment are not
known, it was  previously shown that treatment of Prn greatly
reduced the epitope binding activity by a panel of murine mAbs
and induced antibodies that bound Prn, but was  not bactericidal
[39]. Conversely, the association between antibody responses to
site accessibility is a frequently reported phenomenon for various
antigens [40] and most likely reﬂects the exposure of the antigen
and maturation of the immune system.
Most Pc vaccines are composed of 1, 2 or 3 different strains,
while Pa vaccines by 3–4 components. The Pa vaccine used in our
F.R. da Silva et al. / Vaccine 32 (2014) 6251–6258 6255
Fig. 2. Spatial localization of the linear epitopes recognized by sera from mice immunized with acellular (A) and cellular (B) Bordetella pertussis vaccine in three dimensional
structures of P.133 Prn toxin. The epitopes numbers (Prn-1-25) are highlighted in different colors to facilitate identiﬁcation. The P.133 Prn structure was obtained from
protein  data bank (http://www.pdb.org) and drawn using PyMol. The C-terminal amino acid residues 600–887, are not part of the resolved structure (1DAB.pdb) and was
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tudy included four components; the PT, FHA, ﬁmbrial and Prn pro-
ein. Since both are protective, the common epitopes in the P.69 Prn
ecome the more important targets of the immune response for
eutralization. However, the protective importance of the epitopes
resent in the P.30 segment should not be ignored since there was
 robust response induced specially by the Pc vaccine. Nonetheless,
he reactivity of the Pa vaccine suggests the presence of some P.30
n the Pa vaccine. The industrial process of Pa vaccine preparation
ncludes the use of B. pertussis culture ﬁltrates, which are subjected
o ultraﬁltration on a 30 kDa membrane that could retain P.30.
In relation to the structure-function of the toxin, pertactin pos-
esses two important regions, designated regions 1 (aa 276–280)
nd 2 (aa 575–590 and 594–598), which are comprised of repeats
nown to create polymorphisms that could contribute to immune
scape [41] from their role in conferring immunity in rabbit
29]. However, our analysis showed that these regions were not
mmunogenic in mice after immunization by either vaccine (Fig. 2).
ontiguous regions contain the amino acid triplet RGD, which
as been shown to be involved in adherence to host cells [25].
oth RGD site 1 [aa 257-–265] and 2 [aa 691–693] were discov-
red within epitopes Prn-8 (aa 245–264/257–265) and Prn-18 (aa33aa) and major loop (433–441aa). (For interpretation of the references to color in
682–699/686–699) recognized by sera from the Pc and Pa vac-
cine, which should contribute to neutralization by interfering with
attachment of the bacterium to human cells.
The C-terminal region of the P.69 Prn contains another impor-
tant motif loop [37] that appears to represent the major human
immunoprotective epitope [aa 567–573]. Here, this epitope was not
recognized by either sera obtained after vaccination (Table 1). Like-
wise, the human immunodominant regions composed of repeating
units of 5 (GGXXP) or 3 (PQP) amino acids [8], were not recognized
after vaccination by both the Pa and Pc. However, in general, there
was good correlation between epitopes identiﬁed in this study and
those previously described using murine antibodies (Table 1).
Different factors can inﬂuence antigenicity of an antigen such as
host, strain, adjuvant, antigen concentration and number of injec-
tions for immunization. These factors were similar for both vaccines
in our study. Therefore, the observed differences of antigenicity
against the pertactin within miPa and miPc can be attributed to
antigen preparation. For pertactin, the cellular vaccine has primar-
ily membrane-inserted protein whereas it is puriﬁed in the acellu-
lar vaccine. However, the presence of more lipids could increase
antigenicity of the proteins in the cellular vaccine suggesting
6256 F.R. da Silva et al. / Vaccine 32 (2014) 6251–6258
Fig. 3. Cross-reactivity of epitopes in the P.133 Prn protein for strains of Bordetella pertussis contained or not contained within vaccine preparations [(1) Q03035, (2) K4QEP0,
(3)  K4TPW9, (4) Q9L4E2, (5) Q6U896, (6) K4TCV0, (7) Q9AIX8, (8) K0MTC8, (9) J7RKB0, (10) A4UTL5, (11) F4LFL2, (12) P14283] deposited in data bank. The boxed sequences
represent the 25 IgG epitopes identiﬁed in this work by SPOT-synthesis.
F.R. da Silva et al. / Vaccine 3
Fig. 4. Cross reactivity of the P.133 Prn within Bordetella sp.  (1) Bordetella pertus-
sis  (access number, A4UTL5); (2) B. parapertussis (access number, P24328); (3) B.
bronchiseptica (access number, Q9L4E2). The boxed sequences represent the 25 per-
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1997;3:175–8.actin IgG epitopes identiﬁed in this work by mouse sera vaccinated with Pc and Pa
accine.
hat immunogenicity of the acellular vaccine could be improved
y incorporating a stronger adjuvant than aluminum salts into the
reparation to stimulate Th1 responses. Extensive literature exist
eporting adjuvants that improve antibody responses to pertussis2 (2014) 6251–6258 6257
antigens [42–44], including a recent report for oligosaccharides
derived from a B. pertussis lipopolysaccharide that, when conju-
gated with a protein induced bactericidal antibodies [45].
Vaccination with Pc induces a broad immune response against
hundreds of bacterial proteins while the Pa vaccine-induced
immune response targets the virulence of B. pertussis and not of
B. parapertussis [33], another causative agent. These species are, in
general, immunologically distinct [29], but this study shows that
all of the epitopes induced by Pc vaccine and Pa vaccine shared
common sites within Bordetella sp that includes B. parapertussis
and B. bronchiseptica suggesting that the use of Prn as an immuno-
gen generates a broad reactivity that covers all strains and species
that express and secrete the toxin. However, some isolates are not
affected by vaccination, including their virulence. Therefore, the
absence or decrease in protection afforded by vaccination with both
Pc and Pa does appear not to related to the generation of neutraliz-
ing antibodies against the Prn B. parapertussis protein. Rather, the
results suggest that other virulent factors are present in the circu-
lating strains and species of Bordetella,  which are not addressed by
the current Pc and Pa vaccines.
In conclusion, the peptide arrays formed directly onto cellu-
lose membranes allowed the identiﬁcation of the major antigenic
determinants in the P.133 recognized by mouse sera after being
immunized by either the Pc or Pa vaccine. The epitopes common
and speciﬁc to each vaccine epitopes were determined and located
within a structural model. This study also provides evidence that
antibodies against P.30 are induced by the Pc vaccine and could be
effective in neutralizing the toxin effect.
Mouse is the most frequently used animal in the literature
for investigating immune responses against B. pertussis. Although
humans are the only natural host for this bacterium, mice can
be infected with B. pertussis, and despite the absence of cough
after infection, they present other reactions resembling the human
response and therefore are acceptable as a model for studies on
immunity against this pathogen [46].
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